Edgewise Therapeutics, Inc.
EWTX Nasdaq
SEC CIK 1710072
Follow Edgewise Therapeutics
Weekly email: filings, results
Net income
$1.2B
+2967.6% vs same quarter last year
EPS, diluted
$9.65
+2574.4% vs same quarter last year
Operating cash flow
−$78.3M
−125.1% vs same quarter last year
Operating income
−$46.1M
+1.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$167.8K |
| FY24 | −$133.8K |
| FY23 | −$100.2K |
| FY22 | −$67.6M |
| FY21 | −$42.8M |
| FY20 | −$17.1M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$144.1M |
| FY24 | −$110.3M |
| FY23 | −$97.7M |
| FY22 | −$58.2M |
| FY21 | −$34.2M |
| FY20 | −$14.8M |
| FY19 | - |